Novigenix
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Tamkeen Launches ‘Bahrain Skills and Gender Parity Accelerator’ at Davos22.1.2025 14:00:00 CET | Press release
DAVOS, SWITZERLAND / ACCESS Newswire / January 22, 2025 / The Bahrain Labour Fund (Tamkeen) has partnered with the World Economic Forum (WEF) to launch the Bahrain Skills and Gender Parity Accelerator. The announcement was made at Davos, exemplifying the theme of the 55th Annual Meeting "Collaboration for the Intelligent Age," wherein the data-driven accelerator is aimed at closing the gender skills gap in high-growth industries and at increasing the participation of the current and next generation of the local Bahraini workforce. In the presence of His Highness Shaikh Isa bin Salman bin Hamad Al Khalifa, the Chairman of the Board of Trustees of the Isa bin Salman Education Charitable Trust and Chairman of the Board of Directors the Labour Fund (Tamkeen) and H.E. Shaikh Salman bin Khalifa Al Khalifa, Minister of Finance and National Economy, alongside other key dignitaries; the agreement was signed by H.E. Noor bint Ali Alkhulaif, Minister of Sustainable Development, Chief Executive of
Preservica Academy Launches to Help Information Professionals Accelerate Skills in Active Digital Preservation22.1.2025 09:00:00 CET | Press release
BOSTON, MA and OXFORD, UK / ACCESS Newswire / January 22, 2025 / Preservica, a pioneer of Active Digital Preservation™ archiving, which applies intelligent, embedded and automated preservation to ensure always readable and trusted long-term data, is excited to announce the launch of the Preservica Academy. Delivering a flexible and comprehensive learning program, the Academy is designed to equip both newcomers and seasoned professionals with the skills and expertise needed to safeguard the accessibility and integrity of digital records into the future. The Academy focuses on practical, transferable skills in Active Digital Preservation™, including how to automate preservation actions and how to make Digital Preservation an embedded part of everyday workflows. The aim is to empower participants to enhance their professional development, unlock new career opportunities and master the art of preserving digital records for the long-term. "Preservica Academy is designed for Digital Preserva
Glenmorgan Investments Reopens Digital Asset Innovation Fund22.1.2025 08:00:00 CET | Press release
Glenmorgan Investments Announces the Reopening of Its Digital Asset Innovation Fund to New Investors Following Record-Breaking Performance and Enhanced Regulatory Clarity LONDON, UK / ACCESS Newswire / January 22, 2025 / Glenmorgan Investments Limited, a leading provider of award-winning fund management services since 1999, has announced the reopening of its highly sought-after Digital Asset Innovation Fund to new investors. The fund, which was initially capped in March 2024 due to unprecedented demand, will now have its cap increased to $1 billion from the original $500 million limit, following significant performance milestones and enhanced regulatory clarity in the digital asset landscape. The Digital Asset Innovation Fund, launched in 2018, has delivered exceptional returns, achieving record-breaking performance in 2024 and into 2025. The fund focuses on high-growth opportunities within the digital asset space, including cryptocurrencies and blockchain technology. Amid growing inte
The Now Corporation (OTC:NWPN) Subsidiary, Green Rain Solar Inc., Explores Selling Development Rights for Solar Farm Project in Greece, NY22.1.2025 08:00:00 CET | Press release
PASADENA, CA / ACCESS Newswire / January 22, 2025 / The Now Corporation (OTC PINK:NWPN) through its subsidiary, Green Rain Solar Inc., is actively exploring the sale of development rights for a groundbreaking solar energy project located at 4777 Dewey Avenue, Greece, New York. This strategic move aims to generate funding for the advancement of solar energy projects nationwide. The 19.5-acre site in Greece, NY, is set to host a state-of-the-art ground-mount solar farm. This initiative underscores Green Rain Solar's commitment to developing innovative and sustainable energy solutions that accelerate the transition to net-zero carbon emissions. Green Rain Solar, specializing in urban and distributed solar energy systems, seeks to transform underutilized spaces into renewable energy powerhouses. The sale of development rights for this project will provide the capital needed to enhance further solar initiatives, expand operations, and support clean energy adoption in high-demand regions. "T
ZeroPath Corp. Launches Next-Generation Code Security Platform Powered by Artificial Intelligence22.1.2025 03:00:00 CET | Press release
ZeroPath Security Scanner Launches to Market, Bringing Enterprise-Grade AI Security Analysis to Development Teams SAN FRANCISCO, CA / ACCESS Newswire / January 22, 2025 / ZeroPath Corp., a Y Combinator-backed cybersecurity company, today announced the public launch of its LLM-driven code security platform. The company was previously noted for using its platform to find critical zero-day vulnerabilities in major open-source projects. Alongside the launch, the company also announced the completion of its seed funding round led by SurgePoint Capital, with Y Combinator and angel investor Paul Graham both participating. ZeroPath's security testing platform, among the first of its kind, attempts to combine deep program analysis with large language models to detect more complex security vulnerabilities. The system has previously demonstrated remarkable success in identifying critical security flaws in large open-source repositories, including remote code execution vulnerabilities, authorizati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom